ITI Pharma & Healthcare Fund
Ticker: mf13524
Decent
48/100
☆ Add to Watchlist
More Options
I
ICICI Pru Nifty LargeMidcap 250 Index Fund
The ICICI Pru Nifty LargeMidcap 250 Index Fund presents a decent investment opportunity with a balanced exposure to growth and profitability, though caution is advised due to some valuation concerns and execution risks.
View details
C
Canara Rob Banking and PSU Debt Fund
The fund shows several weaknesses in growth, profitability, and market sentiment, making it a risky investment.
View details
S
SBI Equity Minimum Variance Fund
The SBI Equity Minimum Variance Fund shows a decent overall performance with solid growth and profitability metrics, though some risks remain in execution and market sentiment.
View details
A
Aditya Birla SL FTP-TQ-1879D
The stock shows potential but is hindered by inconsistent growth and valuation concerns. Caution is advised.
View details
A
Aditya Birla SL Dynamic Asset Allocation Omni FOF
The fund shows potential but carries significant risks due to inconsistent growth and valuation concerns.
View details
A
Aditya Birla SL Global Excellence Equity FoF
The fund shows decent potential with strong growth and profitability metrics, but caution is advised due to valuation concerns and execution risks.
View details
P
PGIM India Money Market Fund
The PGIM India Money Market Fund shows decent stability but lacks strong growth drivers and profitability metrics.
View details
T
Tata Nifty200 Alpha 30 Index Fund
The Tata Nifty200 Alpha 30 Index Fund shows potential for steady growth with a diversified portfolio, though some execution risks exist.
View details
Q
Quantum ELSS Tax Saver Fund
The Quantum ELSS Tax Saver Fund shows decent potential with a solid growth trajectory and manageable risks, making it a reasonable choice for investors seeking tax-saving options.
View details
I
ICICI Pru India Equity
ICICI Pru India Equity shows potential for growth, but faces challenges in profitability and valuation metrics. Investors should proceed with caution.
View details
I
IL&FS Infra Debt Fund - Series 2-A
The fund shows potential but is hindered by significant risks and inconsistent performance metrics.
View details
B
Baroda BNP Paribas Dynamic Bond Fund
The fund shows decent potential with stable growth and a solid balance sheet, but faces challenges in governance and market sentiment.
View details
W
WOC Balanced Hybrid Fund
The WOC Balanced Hybrid Fund has potential but faces challenges in growth consistency and valuation metrics. Caution is advised.
View details
P
PGIM India Aggressive Hybrid Equity Fund
The fund shows decent potential with consistent growth and manageable risks, but investors should be cautious of valuation and governance aspects.
View details
Z
Zerodha ELSS Tax Saver Nifty LargeMidcap 250 Index Fund
The fund shows decent potential with a balanced approach to growth and risk, but investors should remain cautious about execution risks.
View details
L
LIC MF Arbitrage Fund
LIC MF Arbitrage Fund presents a decent investment opportunity with stable returns, but potential investors should be cautious of growth inconsistencies and market risks.
View details
Business Overview
The ITI Pharma & Healthcare Fund is a specialized mutual fund focusing on the dynamic pharmaceutical and healthcare sectors. Designed for investors seeking long-term growth, it capitalizes on the increasing demand for healthcare solutions in India. This fund is ideal for those who wish to diversify their portfolio while investing in a sector with significant potential.
- Focuses on pharmaceutical and healthcare industries
- Ideal for long-term investors
- Capitalizes on India's growing healthcare demand
- Diversifies investment portfolios
- Managed by experienced professionals
Investment Thesis
ITI Pharma & Healthcare Fund stands out due to its strong promoter credibility, robust growth potential in digital healthcare services, and attractive valuation compared to peers. This positions it as a compelling investment opportunity in the evolving healthcare landscape.
- Strong backing from a reputable promoter group enhances trust and stability.
- Significant growth potential in digital healthcare services as demand surges.
- Valuation metrics are favorable compared to industry peers, indicating potential upside.
- Focus on innovative healthcare solutions aligns with market trends.
- Diversified portfolio reduces risk and enhances long-term growth prospects.
Peer Perspective
ITI Pharma & Healthcare Fund trades at a premium compared to peers like Nippon India Pharma Fund and SBI Healthcare Opportunities Fund. A sustained improvement in margin stability could trigger a positive rerating.
📊 Stock Investment Checklist (100 Points)
ITI Pharma & Healthcare Fund • Updated: 2025-09-29 14:52:35
-
10BusinessHighPharma sector shows potential but faces regulatory challenges.
-
10GrowthHighConsistent revenue growth observed over the last few years.
-
10ProfitabilityHighROE and ROCE are above industry average, but OCF is inconsistent.
-
8ValuationHighP/E and P/B ratios are higher than peers, indicating potential overvaluation.
-
6BalanceGoodModerate debt levels, but liquidity ratios are concerning.
-
5GovernanceGoodPromoter holding is stable, but some pledging exists.
-
2DriversLowLimited catalysts identified; execution risks are significant.
-
0TechnicalsLowWeak market sentiment and low liquidity.
Final Score & Verdict
Score 48 / 100
• Decent
While the ITI Pharma & Healthcare Fund shows some growth potential, the overall risk factors and valuation concerns suggest a cautious approach.